Keyword: Momenta Pharmaceuticals
Here's a FierceBiotech Radio episode about the Battle of the Biotech Bands, ahead of the podcast's relaunch in 2018.
Lilly's longtime CFO Rice will retire, Akari's CEO resigned amid a false data scandal, MannKind replaced its CEO with the hope to revive Afrezza.
Momenta was up nearly 6% after hours last night when it unveiled a new research deal with CSL Limited for its Fc multimer proteins, months after flopping in a phase 2 cancer test.
Shire has returned rights to the two biosimilars that Baxalta had in development.
Momenta has stopped a Phase II pancreatic cancer trial of necuparanib after an interim futility analysis found a lack of efficacy.